Cellectar Biosciences, Inc. (CLRB) on Tuesday announced positive 12-month follow-up data from its Phase 2b CLOVER WaM study evaluating iopofosine I 131 in patients with Waldenström acroglobulinemia, a rare, slow-growing blood cancer.
The updated dataset, which includes at least 12 months of follow-up for all enrolled patients as requested by the U.S. Food and Drug Administration, showed an overall response rate of 83.6%, while the major response rate reached 61.8%, meeting the study's primary endpoint.
Separately, the company said it has entered into securities purchase agreements with certain institutional investors and members of management to issue and sell up to $140 million in shares.
The financing is expected to support a confirmatory study and the filing of a New Drug Application seeking accelerated approval of iopofosine I 131 for the treatment of Waldenström macroglobulinemia with the FDA.
The company's shares were more than 80% up in pre-market trading after closing at $2.83 on Monday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.